Bristol Myers Squibb (BMY), a prominent pharmaceutical company, continues to display formidable performance in the stock market. It has received positive opinions from the CHMP for its therapies Breyanzi, for relapsed or refractory follicular lymphoma, and Opdivo plus Yervoy, for the treatment of uncontrolled or advanced hepatocellular carcinoma. This expected to increase the demand for its shares. Several institutional investors, including Caprock Group LLC and Union Bancaire Privee UBP SA, express faith in the company as they hold millions in Bristol-Myers shares. However, certain entities like Cibc World Market Inc. and Institute for Wealth Management LLC. recently sold their BMY shares. The company promises considerable dividends to shareholders, which adds to its appeal as a long-term investment. Furthermore, BMY looks forward to participating in the J.P. Morgan's 43rd Annual Healthcare Conference. Bristol Myers Squibb also beats a $6.4 billion lawsuit over a delayed cancer drug, further strengthening its position.
Bristol-Myers Squibb BMY News Analytics from Thu, 30 May 2024 07:00:00 GMT to Sat, 01 Feb 2025 10:55:56 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 5
